Ginkgo Bioworks Holdings, Inc. filings document an operating company focused on cell engineering, autonomous lab services, and biological R&D tools. Form 8-K reports record operating and financial results, material-event disclosures, governance matters, the completed Biosecurity divestiture, and the classification of that former business within discontinued operations.
Proxy and capital-markets filings cover board and shareholder voting matters, executive compensation, equity awards, and governance practices. The filing record also describes Ginkgo's Class A common stock listed on the NYSE under DNA, registration-statement activity, at-the-market offering arrangements, material agreements, and related capital-structure disclosures.
Jason Kelly reports a proposed sale of 109,767 shares of Class A common stock under Form 144. The securities are tied to restricted stock vesting as compensation and dated 04/08/2026. The filing shows 97,015 shares sold during the past three months, with values listed as $702,201.45 and $672,343.05. Trades are noted for the NYSE and the filing header date is 04/09/2026.
Ginkgo Bioworks Holdings, Inc. completed the sale of substantially all operations of its Biosecurity segment to Tower Biosecurity, Inc. on April 3, 2026. In return, Ginkgo received common stock representing approximately 20% of Tower Biosecurity’s fully diluted equity, which will be accounted for under the equity method.
Because this deal represents a strategic shift, Biosecurity’s historical results will be reported as discontinued operations. Unaudited pro forma statements show how Ginkgo’s balance sheet and results for 2023–2025 would look without Biosecurity, with lower revenue but slightly reduced net losses over all three years.
Ginkgo Bioworks Holdings Inc: The Vanguard Group filed an Amendment No. 5 to its Schedule 13G/A reporting 0 shares beneficially owned, representing 0% of Ginkgo Bioworks common stock. The filing explains an internal realignment effective 01/12/2026 that disaggregated certain Vanguard subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries under SEC Release No. 34-39538.
Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported compensation-related equity activity involving restricted stock units (RSUs) and Class A Common Stock. On March 13, 2026, he exercised RSUs covering 1,486 shares, converting them into the same number of Class A shares at a per-share price of $0.0000. Each RSU represents a right to receive one share of Class A stock, and the RSUs vest over time according to pre-set schedules.
On March 16, 2026, Coen sold 708 shares of Class A Common Stock at an average price of $6.7350 per share. A footnote explains these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock and RSUs, and that such “sell to cover” transactions do not represent discretionary trades. Following these transactions, Coen directly owns 9,099 shares of Class A Common Stock.
DNA submitted a Form 144 notice concerning Class A shares. The filing shows 708 Class A shares tied to a Restricted Stock Vesting event on 03/13/2026, with Fidelity Brokerage Services listed as broker. The filing also records a prior sale of 972 Class A shares on 01/20/2026 by Steve Coen.
DNA filing reports notices under Rule 144 to sell Class A shares. The filing lists two reported transactions by Austin Che of 2,200 Class A shares on 01/07/2026 and 02/04/2026, and earlier restricted stock vesting entries dated 10/18/2022 (888 shares) and 10/20/2022 (1,312 shares).
The entries identify Fidelity Brokerage Services LLC and include per-transaction numeric figures (2200) and associated monetary figures shown in the excerpt. This notice-style filing documents planned or reported dispositions; timing and cash-flow treatment are as stated in the entries.
Ginkgo Bioworks Holdings, Inc. entered into a Stock Purchase Agreement under which its wholly owned subsidiary will transfer all issued and outstanding equity of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc. This business represents substantially all of Ginkgo’s Biosecurity segment operations.
In return, Tower Biosecurity will issue shares of its common stock to Ginkgo’s subsidiary, equal to approximately 20% of Tower’s fully diluted equity. The transaction is expected to close in the first half of 2026, subject to customary closing conditions.
Ginkgo Bioworks Holdings reported 2025 revenue of $170.2 million, down from $227.0 million in 2024, as both cell engineering and biosecurity revenue declined. The company’s net loss narrowed to $312.8 million from $547.0 million, helped by large reductions in research and development and general and administrative expenses.
R&D spending fell to $243.8 million and G&A to $183.3 million, reflecting a restructuring begun in 2024, lower headcount and reduced facilities and professional costs. Adjusted EBITDA improved to a loss of $167.0 million from a loss of $293.3 million, showing progress but continued heavy cash burn.
Biosecurity service revenue declined to $37.4 million on weaker government work, while new cell engineering tools such as Datapoints and automation systems drove higher "cost of other revenue" as those offerings scaled. The company ended 2025 with $167.2 million in cash and equivalents and $255.4 million in marketable securities and believes this liquidity will fund operations for at least 12 months.